Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Protein kinase inhibitors can induce retinopathy].

Ugeskrift for laeger - 3 Aug 2020

Lindboe Johanne Bjerre, Ahmed Hassan Javed, Christakopoulos Christos Eleftherios

Abstract excerpt

Novel treatment strategies such as targeted therapy with mitogen-activated protein-kinase-kinase/B-Raf proto-oncogene (MEK/BRAF) inhibitors have prolonged patient survival in metastatic melanoma and are used in oncology. The combination of binimetinib og encorafenib can induce extensive bilateral neuroretinal detachments. In this case report, we present a 72-year-old female patient with this condition. Dilated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins B-raf

Share to Retinal Diseases

Source

Identifiers

PMID: 32800052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

[Protein kinase inhibitors can induce retinopathy].PMID 32800052Read ↗

[MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma].Semantic proximity Read ↗

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.Semantic proximity Read ↗

[Subretinal fluid associated with MEK and BRAF inhibitors].Semantic proximity Read ↗

Bilateral Serous Retinal Detachment Associated with a Mitogen-activated Protein KinaseKinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer.Semantic proximity Read ↗

[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].Semantic proximity Read ↗

Ocular toxicity due to Trametinib and DabrafenibSemantic proximity Read ↗

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Management of Bilateral Diffuse Uveal Melanocytic Proliferation (BDUMP) - A Case ReportSemantic proximity Read ↗

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMASemantic proximity Read ↗

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.